Abstract: The present invention relates to compositions for the oral and vaginal administration of human Lactobacilli and uses thereof for physiologic restoration of the vaginal flora, physiologic maintenance of Lactobacillus flora in pathologic deficiency to produce Lactobacilli, treatment of asymptomatic bacterial vaginosis and prevention of preterm delivery caused through bacterial vaginosis.

Abstract: The present invention relates to compositions for the oral and vaginal administration of human Lactobacilli and uses thereof for physiologic restoration of the vaginal flora, physiologic maintenance of Lactobacillus flora in pathologic deficiency to produce Lactobacilli, treatment of asymptomatic bacterial vaginosis and prevention of preterm delivery caused through bacterial vaginosis.

Abstract: A compound body can be constructed, using secondary cell wall polymers of prokaryotic microorganisms as bonding agent to anchor a monomolecular lattice to a support, with or without functional groups attached to the lattice. The lattice may be comprised of lipid or crystalline cell surface layer proteins. The support is illustrated by a micro-filtration membrane, a cell surface ultra-filtration membrane (SUM), and a micelle, respectively.

Abstract: Use of secondary cell wall polymer for the directed monomolecular bonding of molecules, preferably molecular layers and/or attachment of molecules to molecules of a support, as well as a compound body completed according to this application.

Abstract: Disclosed are methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides. Specifically, in the disclosed methods, sialyltransferase is activated to transfer an analogue of sialic acid, employed as its CMP-nucleotide derivative, to an oligosaccharide glycoside. The analogue of sialic acid and the oligosaccharide employed in this method are selected to be compatible with the sialyltransferase employed.

Abstract: Superior pharmaceutical compositions which comprise carriers coupled to epitope-bearing moieties are described. The carriers are crystalline or paracrystalline glycoproteins, especially those derived from S-layers of microbial cell walls. These conjugates are capable of eliciting the formation of antibodies as well as a T-cell response.

Abstract: Compounds of formula I ##STR1## wherein R.sub.2 and R.sub.3 are the same or different and each represent unsubstituted or substituted acyl,and(a) R.sub.1 represents lower alkyl, aralkyl or the phosphate, pyrophosphate, phosphorylethanolamine or pyrophosphorylethanolamine group, R.sub.4 represents the phosphate, pyrophosphate, phosphorylethanolamine or pyrophosphorylethanolamine group and one of R.sub.1 and R.sub.4 may additionally represent hydrogen and R.sub.5 represents hydrogen or a glycosyl radicalor(b) R.sub.1 represents hydrogen, lower alkyl or aralkyl and R.sub.4 and R.sub.5 represent hydrogen,which compounds are indicated for use as pharmaceuticals, in particular as immunostimulants.